INTRODUCTION {#s1}
============

Li--Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by heterozygous germline mutations in *TP53* ([@MCS003921QUIC13]). Children and adults with LFS are at high risk to develop cancer, most notably sarcomas, adrenocortical carcinomas, brain tumors, and, in women, early-onset breast cancers ([@MCS003921QUIC3]; [@MCS003921QUIC12]). Although initially considered rare, recent estimates suggest an incidence as high as 1:500 and a new mutation (also known as "de novo") rate of 7%--20% ([@MCS003921QUIC8]; [@MCS003921QUIC6]). Although LFS is a well-established cancer predisposition syndrome, tailored predictions of exact cancer risk and type remain unavailable. Although the pathogenicity of recurrent variants located within the *TP53* DNA-binding domain (DBD) is well established ([@MCS003921QUIC10]), limited information is available regarding the clinical and functional implications associated with small in-frame deletions and duplications ([@MCS003921QUIC2]), especially when they are encountered for the first time. Here, we report the process of utilizing segregation, de novo status, and structural and functional evidence to establish the pathogenicity of such a variant.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

A previously healthy 2-yr-old Caucasian male presented with progressive tremors of the left extremity and difficulty walking of 2 mo duration. Magnetic resonance imaging (MRI) of the brain demonstrated a large enhancing thalamic mass ([Fig. 1](#MCS003921QUIF1){ref-type="fig"}). The child underwent a subtotal resection and histologic evaluation showed a high grade poorly differentiated neural tumor ([Fig. 2](#MCS003921QUIF2){ref-type="fig"}). Immunohistochemical assay showed moderate to strong nuclear staining for p53 in most tumor cells. Under normal conditions, wild-type (wt) p53 is unstable and thus difficult to detect by immunohistochemistry. In contrast, mutant p53 has a longer half-life and accumulates in the nucleus ([@MCS003921QUIC21]). The widespread nuclear immunoreactivity for p53 seen in this case suggested the presence of a mutation in *TP53*, an important tumor-suppressor gene.

![MRI image of the brain. MRI image of the brain shows a large mass involving the right thalamus with extension to the left thalamus and down into the right side of the midbrain.](MCS003921Qui_F1){#MCS003921QUIF1}

![Tumor histopathologic analysis. (*A*) A high-grade tumor neural tumor is composed of uniform undifferentiated cells with a high nuclear to cytoplasmic ratio and high mitotic count. (*B*) Almost all tumor cells showed strong nuclear immunoreactivity for p53. Images were taken at 200× magnification.](MCS003921Qui_F2){#MCS003921QUIF2}

Upon reviewing the family history, it was learned that the child\'s mother had been diagnosed with bilateral breast cancer at the age of 32 yr ([Fig. 3](#MCS003921QUIF3){ref-type="fig"}). The breast tumors tested positive for estrogen and progesterone receptors as well as for human epidermal growth factor receptor 2 (HER2/neu); this "triple-positive" phenotype is a cardinal feature of LFS-associated breast cancer ([@MCS003921QUIC14]). The child\'s mother shared that she had undergone germline genetic testing for *BRCA1* and *BRCA2* and no mutations were found. Altogether, the child\'s brain tumor diagnosis, tumor immunoreactivity for p53, and maternal history of early-onset triple-positive breast cancer with negative *BRCA1/2* testing supported the possibility of LFS as the cause for cancer in this family.

![Family pedigree. Family pedigree reveals child with brain tumor and mother with early-onset breast cancer. No other early-onset cancers are reported in the family.](MCS003921Qui_F3){#MCS003921QUIF3}

Genomic Analyses {#s2b}
----------------

Based on the concern for LFS, the child\'s mother was offered germline *TP53* testing. Results revealed that she carried a heterozygous *TP53* variant (c.764_766delTCA; I255del) ([Table 1](#MCS003921QUITB1){ref-type="table"}), consisting of a deletion of codon 255 in exon 7, which normally codes for isoleucine (rs1064794309) ([Fig. 4](#MCS003921QUIF4){ref-type="fig"}). Although this variant was predicted to be deleterious using in silico tools and it was absent from control databases, these criteria alone were not sufficient to call it pathogenic or likely pathogenic according to guidelines from the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP) ([@MCS003921QUIC017]). Therefore the variant was classified as a variant of uncertain significance (VUS).

![Schematic of the p53 protein. Schematic of the p53 protein shows the location of the I255del variant within the DNA-binding domain.](MCS003921Qui_F4){#MCS003921QUIF4}

###### 

Variant table

  Gene     Variant                         Chr   HGVS DNA Ref.   HGVS protein Ref.   Variant type             Predicted effect   dbSNP ID       Genotype       ClinVar ID       Parent of origin               Observed effect
  -------- ------------------------------- ----- --------------- ------------------- ------------------------ ------------------ -------------- -------------- ---------------- ------------------------------ --------------------------------------------------------------------------
  *TP53*   c.764_766delTCA (p.Ile255del)   17    NM_000546.5     NP_000537.3         3-nt in-frame deletion   Deletion           rs1064794309   Heterozygous   SCV000629866.1   De novo in proband\'s mother   Deletion in DBD impairs p53 transcriptional activity and protein folding

Because the family history and tumor types were highly suspicious for LFS, additional evidence of pathogenicity was sought. Approaches to obtain additional information regarding the clinical significance of a VUS are to assess whether it tracks with disease (segregates) in the family and to determine whether it is new (de novo) in an affected individual. In the case of the family presented here, targeted germline testing for the *TP53* I255del variant in the child would provide information about segregation, whereas testing both maternal grandparents might make it possible to determine de novo status.

The child expired while his mother was undergoing genetic testing. Therefore, archived germline DNA was sent for *TP53* analysis. Through this testing, the child was found to also carry the *TP53* I255del variant. Subsequent testing of the maternal grandparents demonstrated that neither carried the variant ([Fig. 3](#MCS003921QUIF3){ref-type="fig"}), suggesting that this variant occurred as a de novo mutation in the mother. With this additional information, the *TP53* I255del variant was reclassified by the testing laboratory as likely pathogenic, thereby confirming the diagnosis of LFS in the deceased child and his mother.

Structural and Functional Analyses {#s3}
----------------------------------

*TP53* encodes the p53 protein, a critical transcription factor essential for numerous cellular processes such as DNA repair, cell cycle arrest, apoptosis, and senescence ([@MCS003921QUIC4]). The *TP53* I255del variant is located within the p53 DBD ([Fig. 4](#MCS003921QUIF4){ref-type="fig"}), where the majority of LFS-associated mutations are found ([@MCS003921QUIC2]). Most *TP53* variants affecting this domain are located at residues involved in contacting DNA or supporting the structure of the DNA-binding surface. Accordingly, these mutations result in a protein with impaired ability to bind DNA and altered regulation of downstream target genes. In the case presented here, the three-nucleotide deletion is predicted to lead to loss of a single amino acid with retention of an intact reading frame. Because it was not clear whether such a change would impact the function of the resulting encoded p53 protein, experiments were performed to examine whether the *TP53* I255del variant impacted the structure or function of the encoded p53 protein.

Structural modeling showed that deletion of I255 causes a one residue register shift in β-pleated sheet 10 of the p53 DBD, resulting in the burial of glutamate 258 (E258) rather than leucine 257 (L257) in the hydrophobic core ([Fig. 5](#MCS003921QUIF5){ref-type="fig"}), which would likely dramatically destabilize the protein. To test this hypothesis, we computationally estimated the free energy (Δ*G*) of folding of the wt-DBD and the I255 deletion mutant (DBD-I255del). Consistent with our hypothesis, the Δ*G* of folding was predicted to be −8.2 and +2.9 kcal/mol for wt-DBD and DBD-I255del, respectively; the positive value indicates that the I255del p53 DBD mutant is likely to be thermodynamically unstable. We attempted to confirm this experimentally with recombinant proteins expressed in *Escherichia coli*, but although the DBD-I255del protein bearing well-characterized triple mutations that stabilize the DBD (see Methods) was expressed in bacteria, it was insoluble upon bacterial lysis (data not shown), suggesting that the expressed protein aggregates into inclusion bodies, consistent with the computational prediction that deletion of I255 significantly destabilizes the fold of the DBD. When expressed in p53 null Saos-2 cells, the I255del variant failed to activate transcription of a luciferase reporter under the control of a p53 responsive element. Indeed, p53 I255del was as defective as p53 R175H, the most frequent somatic p53 mutant found in cancer and a known nonfunctional variant ([Fig. 6](#MCS003921QUIF6){ref-type="fig"}). Furthermore, p53 I255del failed to suppress cell growth, as revealed by the significantly greater number of colonies generated by Saos-2 cells transfected with constructs encoding I255del or R175H as opposed to cells transfected with wt p53 ([Fig. 7](#MCS003921QUIF7){ref-type="fig"}).

![Structural modeling of the *TP53* I255del variant. The location of residues in β10 following I255 of the p53 DBD are shown on the crystal structure (PDB 1TUP). Homology models of the I255del mutant show that a register shift in the second half of β10 would result in burial of E258 in a hydrophobic pocket formed by Y107, F109, L145, V147, P151, T155, and Y220 (shown in surface representation). The location of E258 in the I255del mutant model is depicted with the carbon atoms in magenta. The *inset* shows a zoomed-in view of the L257 pocket. Other portions of the protein are shown in cartoon representation. The zinc atom is shown as a sphere. Nitrogen atoms are colored blue; oxygen atoms are colored red.](MCS003921Qui_F5){#MCS003921QUIF5}

![The p53 I255del mutant exhibits reduced transcriptional activity. Constructs encoding p53 wt (*TP53*-wt), p53-R175H (*TP53*-R175H), and p53-I255del (*TP53*-I255del) were transiently transfected into p53-deficient Saos-2 cells. Transcriptional activity was assessed using a promoter--reporter assay. (*A*) The relative p53 luciferase activity was significantly reduced in cells transfected with *TP53*-I255del as compared to *TP53*-wt (*P* \< 0.001) and was like that observed in cells transfected with *TP53*-R175H. (*B*) Corresponding p53 protein expression was determined by western blot analysis. Data represent two independent experiments, with each experiment comprising two biologic replicates.](MCS003921Qui_F6){#MCS003921QUIF6}

![The p53 I255del mutant fails to suppress colony formation. Saos-2 cells were transfected with constructs encoding p53 wt (*TP53*-wt), p53-R175H (*TP53*-R175H), and selected in medium containing G418. (*A*) *TP53*-I255del did not suppress colony formation with respect to *TP53*-wt, with the number of colonies like that produced with the defective *TP53*-R175H (*P* = 0.0026). (*B*) Corresponding colony numbers for each construct are shown with error bars representing the standard deviation. Data represent two independent experiments, with each experiment comprising two biologic replicates.](MCS003921Qui_F7){#MCS003921QUIF7}

Collectively, these clinical (segregation, de novo), structural, and functional studies reveal that the *TP53* I255del variant is tightly linked with tumor formation and is significantly compromised in its ability to regulate transcriptional activity and suppress tumor cell colony formation. These data provide strong evidence supporting the pathogenicity of the *TP53* I255del variant and further confirm its causative role in LFS.

DISCUSSION {#s4}
==========

In-frame 3-base pair (bp) deletions affecting *TP53* have only rarely been reported. A search of the ClinVar database ([@MCS003921QUIC11]) (<http://www.ncbi.nlm.nih.gov/clinvar/>) downloaded 02.17.19, which contains information on 1390 *TP53* variants ([Supplemental Table 1a](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003921/-/DC1)), returns only 10 (0.7%) in-frame 3-bp deletions, including the I255del variant described in this report ([Supplemental Table 1b](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003921/-/DC1)). Except for the I255del variant, each of these nine 3-bp in-frame deletion variants is classified as a VUS. Experimental studies investigating changes in protein structure and function for these nine variants are not yet available; as such, their functional significance remains unknown. Nevertheless, the PROVEAN software tool ([@MCS003921QUIC5]) (<http://provean.jcvi.org/index.php>) predicts a deleterious effect on protein function for all but two of these variants ([Supplemental Table 1b](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003921/-/DC1)). A similar search of the IARC database ([@MCS003921QUIC2]) (R19; <http://p53.iarc.fr>), the largest comprehensive repository of data on families with germline *TP53* mutations and somatic *TP53* variations linked to cancer, reveals a total of eight 3-bp in-frame deletions, including I255del ([Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003921/-/DC1)). Of the remaining seven variants, two are reported in ClinVar, both as VUS. By completing additional genetic and functional studies on the p.I255del 3-bp in-frame deletion identified in our family, we were able to show that this *TP53* variant significantly impacted the structure and the function of the encoded protein. Therefore, we argue that the other reported in-frame 3-bp deletion variants in ClinVar warrant further investigation as it is possible that they too exert negative effects upon the encoded p53 protein, especially the variants located in the *TP53* DBD ([Supplemental Table 1b](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003921/-/DC1))

As *TP53* is increasingly included in multigene panels for cancer susceptibility testing ([@MCS003921QUIC16]), it is inevitable that many more *TP53* variants including in-frame deletion variants will be discovered. In the absence of supporting clinical or functional information, many of these variants will remain classified as VUS. This is problematic as a VUS may cause undue distress and confusion for the patient and family. With additional evidence, a VUS may eventually be reclassified as pathogenic/likely pathogenic or benign/likely benign. In such cases, it is often the clinical laboratory\'s position to recontact health-care providers and/or patients with the newly assigned classification. However, it may take years before the desired evidence for precise variant reclassification is obtained. Therefore, it is important that individuals with a VUS, as well as their health-care providers, maintain an ongoing dialogue to ensure proper communication about the possibility of an updated classification and its potential impact on risk assessment or provision of care.

If there are concerns that the VUS in question may be pathogenic (i.e., affects a residue in a conserved domain or occurs in an individual with a relevant tumor type or suspicious family history), it is important to attempt to gather further evidence. Accurate classification is essential as the information gained informs cancer risk and guides clinical management through institution of cancer surveillance and risk reducing measures. Recent reports suggest that surveillance using whole-body MRI and other radiologic and biochemical testing can detect asymptomatic tumors in individuals with LFS, leading to improved survival ([@MCS003921QUIC19]). Based on these and other data, the National Comprehensive Cancer Network has recently published surveillance guidelines for adults with LFS and recommends discussion of bilateral mastectomy to reduce the risk of early-onset breast cancer (National Comprehensive Cancer Network; Genetic/Familial High-Risk Assessment: Breast and Ovarian \[version 2.2019\]).

Although the case presented here highlights LFS and the challenges of interpreting a germline *TP53* VUS, the processes encountered are highly pertinent to other genetic conditions, the testing of their respective genes, and interpretation of results. It is important that providers understand that although most VUSs are not considered clinically "actionable," there are cases that warrant further investigation. In such cases, it may be necessary to interrogate the genetic origin of the VUS within a family or examine its impact on the functions of the encoded protein. Genetic evaluation of family members may be difficult because of death, estrangement, or disinterest in testing by close relatives. Moreover, functional analysis may be problematic because of a lack of appropriate assays or laboratories willing to perform them. Nevertheless, an upgraded classification to pathogenic or likely pathogenic can provide a family with an understanding of disease causality and significantly impact the approach to clinical management.

METHODS {#s5}
=======

*TP53* Genomic Analysis {#s5a}
-----------------------

All diagnostic *TP53* analysis was done at Invitae, San Francisco, CA. Genomic DNA obtained from the submitted samples was enriched for targeted regions using a hybridization-based protocol and sequenced using Illumina technology at a read depth of ≥50× ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003921/-/DC1)). Reads were aligned to a reference sequence (GRCh37/UCSC hg19), and sequence changes were identified and interpreted in the context of the following *TP53* transcript: NM_000546.5. Enrichment and analysis focused on the coding sequence of the transcript with 10 bp of flanking intronic sequence. The *TP53* promoter, untranslated regions, and other noncoding regions were not interrogated.

P53 Structural Analysis {#s5b}
-----------------------

SWISS-MODEL ([@MCS003921QUIC1]) was used to construct homology models of the wt and I255del p53 DBD constructs both in the wt and in the stabilized M133L/V213A/N268D (LAD) triple-mutant background ([@MCS003921QUIC9]) from the same template (PDB 1TUP). The free energy of folding was estimated using FoldX ([@MCS003921QUIC18]). The Δ*G* of folding was predicted to be −6.2 and +1.6 kcal/mol for LAD-DBD and LAD-DBD-I255del, respectively.

The p53-DBD construct bearing the stabilizing M133L/V213A/N268D mutations has been described previously ([@MCS003921QUIC7]). The I255 deletion was introduced into the triple mutant construct using QuikChange mutagenesis (Agilent). *E. coli* cells expressing the DBD construct were grown in LB at 37°C to an OD of ∼0.8 and induced with 0.5 mM IPTG and 50 µM zinc acetate overnight at 16°C. Cells were harvested by centrifugation, resuspended in buffer containing 50 mM tris, 500 mM NaCl, and 0.5 mM TCEP at pH 8.0, and lysed with a microfluidizer. Lysate was spun down at 30,000*g* and samples were ran on SDS-PAGE before and after lysis.

P53 Functional Analysis {#s5c}
-----------------------

### Cell Culture {#s5c1}

The human osteosarcoma cell line Saos-2 (*TP53*-null) was maintained as a monolayer in Dulbecco\'s modified Eagle\'s medium with [l]{.smallcaps}-Glucose (ThermoFisher Scientific) supplemented with 10% fetal bovine serum, MEM Non-Essential Amino Acids solution (ThermoFisher Scientific), 2.5 mmol/[l]{.smallcaps}-Glutamine and penicillin-streptomycin at 37°C under 5% CO~2~. Cells were seeded at a density of 1 × 10^6^ in 10-cm^2^ plates and used for luciferase promoter--reporter, western blotting, and colony reduction assays.

### Plasmid Construction and Cellular Transfection {#s5c2}

The c.764_766delTCA (I255del) mutant *TP53* was constructed via site directed mutagenesis using QuikChange II kit (Stratagene) with the forward primer: 5′ CCC ATC CTC ACC ATC ACA CTG GAA GAC TCC AG 3′ and reverse primer: 5′ CTG GAG TCT TCC AGT GTG ATG GTG AGG ATG GG 3′ and pCMV-Neo-Bam expression vector containing wt *TP53* cDNA as template. wt and R175H mutant *TP53* cDNA were included as controls ([@MCS003921QUIC20]). The entire coding sequence of each plasmid was confirmed by direct sequencing. Saos-2 cells were transiently cotransfected with 250 ng of p50-2 luciferase reporter construct containing consensus p53 element and 1 µg pCMV-Neo-Bam (vector only) or with 1 µg of pCMV-Neo-Bam expressing wt p53 (*TP53*-wt) or p53-R175H (*TP53*-R175H) or p53-I255del (*TP53*-I255del) mutant cDNA by calcium phosphate, as previously described ([@MCS003921QUIC22]).

### Luciferase TP53 Transcriptional Activation Assay {#s5c3}

Cells were harvested and lysed in M-PER buffer (Pierce Chemical) containing a complete protease-inhibitor cocktail (Roche Diagnostics Corporation). Protein yield was determined by the Bradford method (Bio-Rad Laboratories). The relative luciferase activity was determined 48 h after transfection using a single Luciferase Assay System (Promega) as per the manufacturer\'s directions. For the assay, 20 µL of protein lysate was transferred to 100 µL Luciferase Assay Reagent, followed by 2-sec measurement delay followed by a 10-sec measurement read for luciferase activity in an Optocomp I luminometer (MGM Instruments). Relative light units (RLUs) were normalized to total protein ([@MCS003921QUIC15]).

### Protein Analysis {#s5c4}

Total protein extracts (20 µg) were separated on 4% to 12% NuPAGE protein gel (ThermoFisher Scientific) and transferred to nitrocellulose membranes. The membrane was incubated with mouse monoclonal anti-human p53 DO-1 antibody (1:500; Calbiochem) and mouse monoclonal β-Actin antibody (1:4000; Sigma-Aldrich) with correspondent secondary antibodies. Membranes were imaged using a LI-COR Odyssey infrared scanner.

### Colony Reduction Assay {#s5c5}

For colony reduction assay, cells were maintained and transfected in duplicate. Cells were selected in medium containing 800 ng/mL G418 antibiotic (Invitrogen) 48 h after transfection and maintained for up to 21 d with change of media every 3 d. Cells were washed with Dulbecco\'s Phosphate Buffered Saline (D-PBS), fixed with 100% methanol, and stained with 1:20 Giemsa stain for 45 min, washed briefly, and air-dried before visualization. The colonies were photographed and counted manually and by using ImageJ software ([@MCS003921QUIC17]). Data were reported as percent reduction relative to empty vector-transfected controls.
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